Pharma Mar Investor Relations Material
Latest events
Q4 2023
Pharma Mar
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Pharma Mar S.A.
Access all reports
Pharma Mar, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company is also involved in the production of cytostatic products from plants; research into new molecules and marine organisms; provision of services for diagnosing cancer; and creation of molecules that inhibit the function of genes involved in human diseases. In addition, it offers RNA interference (RNAi) technology platform to design pharmaceuticals that act as synthetic RNAs targeting specific sequences by impairing the expression or activity of a protein to prevent the onset or progression of an illness or disease.
Key slides for Pharma Mar S.A.
Corporate Presentation
Pharma Mar S.A.
Corporate Presentation
Pharma Mar S.A.
Latest articles
Sundar Pichai: CEO of Alphabet and Google
Explore Sundar Pichai's improbable journey from Chennai, India, to becoming one of the most powerful individuals on the planet.
19 Apr 2024
The Three Cornerstones of Serial Acquirer Success
Explore what is behind successful serial acquirers: efficient capital use, decentralization, and a strong focus on people.
19 Apr 2024
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Ticker symbol
Country
🇪🇸 Spain